Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus SULFAMYLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus SULFAMYLON.
MYTREX F vs SULFAMYLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
Sulfamylon (mafenide acetate) is a synthetic sulfonamide that exerts bacteriostatic activity against a wide range of Gram-negative and Gram-positive organisms. It acts by inhibiting the enzyme dihydropteroate synthase, which is involved in folate synthesis, thereby blocking bacterial DNA replication. Additionally, it may be bactericidal at high concentrations via inhibition of cell wall synthesis.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
Topical: Apply a thin layer to the wound once or twice daily. Maximum coverage area should not exceed body surface area of 20%.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
The terminal elimination half-life is approximately 7-8 hours in patients with normal renal function. In renal impairment, half-life may be prolonged, requiring dosing adjustments.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Primarily renal excretion as unchanged drug and its metabolite; approximately 87% of a dose is recovered in urine within 24 hours as sulfacetamide and its deacetylated metabolite, with about 10% as unchanged drug. Less than 2% is excreted in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic